🇺🇸 Search Americas

Global entity results · articles filtered to FDA

35 intelligence results for “HIV-1”

12 patents · 11 trials · 12 pipelines

🇺🇸 Americas articles · global entities

Top match · Patent

HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use The United States of America, as represented by the Secretary, Department of Health and Human Services View profile →

Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope The United States of America, as represented by the Secretary, Department of Health and Human Services
Compare
Recombinant HIV-1 envelope proteins and their use The United States of America, as represented by the Secretary, Department of Health and Human Services
Compare
HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use The United States of America, as represented by the Secretary, Department of Health and Human Services
Compare
Glycan-masked engineered outer domains of HIV-1 gp120 and their use The United States of America, as represented by the Secretary, Department of Health and Human Services
Compare
10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use The United States of America, as represented by the Secretary, Department of Health and Human Services
Compare

All results

Patents (12)

Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope — The United States of America, as represented by the Secretary, Department of Health and Human Services
Recombinant HIV-1 envelope proteins and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
Glycan-masked engineered outer domains of HIV-1 gp120 and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
Neutralizing antibodies to HIV-1 Env and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
HIV-1 Env fusion peptide immunogens and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
Recombinant HIV-1 envelope proteins and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
Compositions and methods for in vivo excision of HIV-1 proviral DNA — United States Government as represented by the Department of Veterans Affairs
Glycan-masked engineered outer domains of HIV-1 gp120 and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
Neutralizing antibodies to HIV-1 GP41 and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services
Recombinant HIV-1 envelope proteins and their use — The United States of America, as represented by the Secretary, Department of Health and Human Services

Trials (11)

Pipelines (12)

B/F/TAF — Gilead Sciences Ireland UC · phase 3
B/F/TAF (Adult Strength) — Gilead Sciences Ireland UC · phase 3
Bictegravir — Gilead Sciences Ireland UC · phase 3
Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM ISL/LEN, ISLATRAVIR/LENACAPAVIR, ISLATRAVIR/LENACAPAVIR, PTM Biktarvy — Gilead Sciences Pty Limited · phase 3
Dovato 50 mg/300 mg film-coated tablets, Dovato 50 mg/300 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Vocabria 400 mg prolonged-release suspension for injection, Vocabria 600 mg prolonged-release suspension for injection — ViiV Healthcare Pty Ltd · phase 3
GS-1720, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-4182 — Gilead Sciences Pty Limited · phase 3
GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720 — Gilead Sciences Pty Limited · phase 3
LAMIVUDINE AND DOLUTEGRAVIR , DARUNAVIR , DORAVIRINE , DARUNAVIR AND COBICISTAT , EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT, TENOFOVIR ALAFENAMIDE , RITONAVIR , ISLATRAVIR/LENACAPAVIR, LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR AND COBICISTAT, EMTRICITABINE, RALTEGRAVIR , EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, EMTRICITABINE, TENOFOVIR DISOPROXIL AND RILPIVIRINE, DOLUTEGRAVIR , LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE, — Gilead Sciences Pty Limited · phase 3
PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS — Gilead Sciences Pty Limited · phase 3
Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets — Merck Sharp and Dohme · phase 3
Rukobia 600 mg prolonged-release tablets — ViiV Healthcare Pty Ltd · phase 3
Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS — Gilead Sciences Pty Limited · phase 3

Breaking Signal

Regulatory Watch

Industry Pulse

Regional Command Centers

Market Dynamics

Congress & Calendar

Company Intelligence

Pipeline & IP

Watchlist

Drug Intelligence

Therapeutic Areas

Clinical Development

Analysis & Commentary

Reports & Whitepapers

Professional Tools

Explore Entities

Continue Researching

Therapeutic Areas

Regulatory Intelligence

🇺🇸 Search Americas

Patents

Popular Pharma Companies

Regulatory Agencies

Popular Drugs

Trending Topics

Trending Diseases

🇺🇸 Search Americas

Patents

Stay Ahead in Pharma